Zyversa Therapeutics Inc ZVSA
$0.31 $0.24 (43.30%) 1D
Last Updated: Jul 17, 12:00 AM·OOTC
Pricing for US stocks is delayed by 24 hours
ZVSA Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Zyversa Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Zyversa Therapeutics Inc. Stock Analysis ZVSA
United States Health Care Nano Cap ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Weston, Florida and currently employs 6 full-time employees. The company went IPO on 2021-12-21. The firm is focused on leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases. Its lead renal drug candidate, Cholesterol Efflux Mediator VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is in development to treat multiple renal indications. Its lead anti-inflammatory drug candidate, Inflammasome ASC Inhibitor IC 100, is a humanized monoclonal antibody in development to treat multiple inflammatory diseases. Its renal pipeline is initially focused on rare, chronic glomerular diseases. Its lead indication for VAR 200 is focal segmental glomerulosclerosis. VAR 200’s active ingredient, 2-hydroxypropyl-beta-cyclodextrin, comprises seven sugar molecules bound together in a 3-D ring with a hydrophobic core and hydrophilic exterior. VAR 200 mediates cholesterol efflux both passively and actively by interacting with hydrophilic components of the glomerular membrane.
Zyversa Therapeutics Inc (ZVSA) Chart
Financial Metrics & Statements of Zyversa Therapeutics Inc (ZVSA)
FAQ's for Zyversa Therapeutics Inc (ZVSA)
- As of August 2026, Zyversa Therapeutics Inc ZVSA is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Zyversa Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Zyversa Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Zyversa Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Zyversa Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Zyversa Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Zyversa Therapeutics Inc (ZVSA)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
